Pages that link to "Q46042032"

The following pages link to Benefit design and specialty drug use. (Q46042032):

Displaying 45 items.

• Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia (Q28396345) (← links)
• Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis (Q30560856) (← links)
• Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis (Q33572753) (← links)
• Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends (Q33572758) (← links)
• The value of specialty oncology drugs (Q33618746) (← links)
• Sexually transmitted diseases among users of erectile dysfunction drugs: analysis of claims data (Q33630092) (← links)
• Innovation and The Welfare Effects of Public Drug Insurance (Q33834130) (← links)
• The working patient with cancer: implications for payers and employers (Q33932131) (← links)
• Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices (Q33942677) (← links)
• Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study (Q34013509) (← links)
• Growth hormone and health policy (Q34086606) (← links)
• Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis (Q34248283) (← links)
• A review of approaches for the management of specialty pharmaceuticals in the United States (Q34402542) (← links)
• Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007-11. (Q34600764) (← links)
• Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D. (Q35210630) (← links)
• Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. (Q35731438) (← links)
• The high cost of cancer drugs and what we can do about it. (Q36512856) (← links)
• A study on the factors affecting the prescription of injection medicines in Iran: a policy making approach. (Q36712899) (← links)
• Cancer's next frontier: addressing high and increasing costs (Q36824884) (← links)
• Prescription drug cost sharing: associations with medication and medical utilization and spending and health. (Q36869615) (← links)
• Flexibility in biologic benefit designs can deliver big rewards. (Q37118528) (← links)
• Out-of-pocket medication costs and use of medications and health care services among children with asthma (Q37125842) (← links)
• Opportunity, resources, and affordability: multistakeholder perspectives. (Q37243372) (← links)
• Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes (Q37248775) (← links)
• New challenges to medicare beneficiary access to mAbs (Q37273474) (← links)
• Financial Consequences of Improved Treatments for Colorectal Cancer (Q37336628) (← links)
• Impacts of health insurance benefit design on percutaneous coronary intervention use and inpatient costs among patients with acute myocardial infarction in Shanghai, China (Q38131463) (← links)
• Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study (Q38665413) (← links)
• Cost-control mechanisms in Canadian private drug plans (Q38963991) (← links)
• End-of-Life Care Matters: Palliative Cancer Care Results in Better Care and Lower Costs (Q39185434) (← links)
• Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval (Q39198395) (← links)
• Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. (Q40327176) (← links)
• Patient medication adherence: the forgotten aspect of biologics. (Q42946255) (← links)
• Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. (Q45212989) (← links)
• Biosimilar growth hormone (Q45254568) (← links)
• Use of and spending on supportive care medications among Medicare beneficiaries with cancer. (Q45999039) (← links)
• Applying Value-Based Insurance Design To High-Cost Health Services (Q46638150) (← links)
• Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases (Q47325212) (← links)
• Out-of-pocket payments in arthritis: spur to prudent purchasing or red herring? (Q50639746) (← links)
• Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a (Q51347635) (← links)
• The Price Elasticity of Specialty Drug Use: Evidence from Cancer Patients in Medicare Part D. (Q52611699) (← links)
• The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study (Q58096487) (← links)
• Biologics and the Principles of Health Insurance: What is the purpose of health insurance? This review of basic insurance concepts provides a context for discussions about coverage of biologics (Q84758057) (← links)
• Rural-urban disparities in the utilization of mental health inpatient services in China: the role of health insurance (Q88197830) (← links)
• Growing Number Of Unsubsidized Part D Beneficiaries With Catastrophic Spending Suggests Need For An Out-Of-Pocket Cap (Q89473939) (← links)